A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor Use
Juan Shen(BGI Group (China)), Bin Zhao(Chinese Academy of Medical Sciences & Peking Union Medical College), Jincheng Yang(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 25
Related Papers
NMI and IFP35 serve as proinflammatory DAMPs during cellular infection and injury
|Nature Communications|2017|127
Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system
|International Immunopharmacology|2020|98
LBA51 KEYNOTE-024 5-year OS update: First-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumour proportion score (TPS) ≥50%
|Annals of Oncology|2020|96
Fournier Gangrene Associated with Sodium-Glucose Cotransporter-2 Inhibitors: A Pharmacovigilance Study with Data from the U.S. FDA Adverse Event Reporting System
|Journal of Diabetes Research|2020|54
Intrinsically disordered CsoS2 acts as a general molecular thread for α-carboxysome shell assembly
|Nature Communications|2023|54